Announcements Trials
Browse Landscape

Phase

Phase 1/2 6Phase NA 5Phase 2 2Phase 1 2Phase 3 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 6Breast 6Other hematologic neoplasm 5Gastrointestinal 5CNS 5Plasma cell 3Thoracic 2Lymphoid 2Sarcoma 1Other neoplasm 1Myeloid 1

Conditions

Lymphoma 900Lymphoma, Non-Hodgkin 685Leukemia, Lymphocytic, Chronic, B-Cell 665Lymphoma, Large B-Cell, Diffuse 617Precursor Cell Lymphoblastic Leukemia-Lymphoma 605Lymphoma, Follicular 516Hodgkin Disease 442Lymphoma, Mantle-Cell 421Leukemia 410Lymphoma, B-Cell, Marginal Zone 289Burkitt Lymphoma 285Recurrence 277Leukemia, Myeloid, Acute 276Multiple Myeloma 250Myelodysplastic Syndromes 237Waldenstrom Macroglobulinemia 187Lymphoma, B-Cell 179Lymphoma, Large-Cell, Immunoblastic 153Lymphoma, T-Cell, Cutaneous 143Leukemia, Myelogenous, Chronic, BCR-ABL Positive 127Lymphoma, T-Cell, Peripheral 123Mycosis Fungoides 118Myeloproliferative Disorders 112Lymphoma, Large-Cell, Anaplastic 107Dendritic Cell Sarcoma, Interdigitating 103Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 102Neoplasms 98Lymphoma, Extranodal NK-T-Cell 96Hematologic Neoplasms 96Sezary Syndrome 94

Interventions

venetoclax 1ofatumumab 1obinutuzumab 1ibrutinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Disease × Lymphoid × Clear all
NCT01613300 2021-05-26

Study of OFATUMUMAB as Part of the Scheme of Reduced Intensity Conditioning in High Risk Non-Hodgkin Lymphoma B Patients

Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea

Phase 2 Completed
33 enrolled
Lymphoid

Disease, Lymphoma, B-Cell

NCT03755947 2021-02-02

Ibrutinib, Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic Leukemia

Grupo Cooperativo de Hemopatías Malignas

Phase 2 Completed
3 enrolled
LymphoidOther hematologic neoplasm

Disease, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡